Prospective study on blood pressure, lipid metabolism and erythrocytosis during and after androgen abuse

Androgen abuse is associated with unfavourable changes in blood pressure, lipid metabolism and erythrocytosis. Most knowledge is based on cross-sectional studies sensitive to bias. We assessed the magnitude of these effects and their recovery in a prospective cohort study which included 100 men (≥18 years) performing an androgen cycle. Clinic visits took place before the cycle, at the end, 3 months after and 1 year after start of the cycle and included measurement of blood pressure, lipid parameters and haematocrit. During androgen use, systolic and diastolic blood pressure increased 6.87 (95% CI 4.34–9.40) and 3.17 mmHg (1.29–5.04) compared to baseline respectively. LDL cholesterol and ApoB increased 0.45 mmol/L (0.29–0.61) and 18.2 mg/dl (13.5–22.8) respectively, whereas HDL cholesterol, ApoA and Lp(a) decreased with 0.40 mmol/L (−0.45 to 0.35), 36.6 mg/dl (30.2–42.9) and 37.6% (13.9–61.3). ANGPTL3 increased 20.3% (7.38–33.2). Mean haematocrit increased 0.03 L/L (0.02–0.03). Three months after the cycle, and 1 year after the start, these parameters returned to baseline. In conclusion, androgen abuse induces small but clinically relevant adverse changes in blood pressure, lipid metabolism and erythrocytosis which are rapidly reversible after cessation. As follow-up was limited to 1 year, the impact of androgen abuse on cardiovascular disease remains uncertain.